David A. Siegel Cyclo Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

  • $42.8 Billion
  • Q1 2025

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$2.62 - $4.51 $26,724 - $46,002
-10,200 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$3.47 - $7.34 $6,940 - $14,680
-2,000 Reduced 16.39%
10,200 $38,000
Q3 2021

Nov 15, 2021
BUY
$6.21 - $10.04 $75,762 - $122,487
12,200 New
12,200 $82,000

Others Institutions Holding CYTH

# of Institutions
2
Shares Held
749K
Call Options Held
0
Put Options Held
0
View Full List

About Cyclo Therapeutics, Inc.

CYTH Quotes by TradingView
  • Ticker CYTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 8,439,440
  • Market Cap $6.08M
  • Description
  • Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...
More about CYTH
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email